Achieve Life Sciences (ACHV) Return on Capital Employed (2011 - 2018)
Achieve Life Sciences' (ACHV) quarterly Return on Capital Employed came in at 260.67% in Q4 2018, down 10187.0% YoY from N/an in Q4 2017, and up 578.53% on a QoQ basis from 54.47% in Q3 2018.
Achieve Life Sciences (ACHV) Return on Capital Employed (2011 - 2018) Analysis & Trends
Achieve Life Sciences (ACHV) has 6 years of Return on Capital Employed data on file, last reported at 260.67% in Q4 2018.
- Quarterly Return on Capital Employed fell 10187.0% year-over-year to 260.67% in Q4 2018, while the trailing twelve-month figure through Dec 2018 was 260.67% (down 10187.0% YoY) and the FY2019 annual result came in at 94.23%, down 40120.0% from the prior year.
- Return on Capital Employed advanced to 260.67% in Q4 2018, from 54.47% in the prior quarter.
- In the past five years, Return on Capital Employed ranged from a high of 490.96% in Q1 2017 to a low of 189.91% in Q1 2018.
- A 4-year average of 166.83% and a median of 204.17% in 2016 frame the typical range for Return on Capital Employed.
- Annual changes were most pronounced in 2017 — Return on Capital Employed jumped 16916 bps — and 2018, when it sank 68087 bps.
- Tracing ACHV's Return on Capital Employed over 4 years: stood at 114.02% in 2015, then surged by 79 bps to 204.17% in 2016, then soared by 78 bps to 362.54% in 2017, then retreated by 28 bps to 260.67% in 2018.
- The last three Return on Capital Employed figures came in at 260.67% (Q4 2018), 54.47% (Q3 2018), and 128.41% (Q2 2018), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 20.76% |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 10.74% |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -55.45% |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 13.68% |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -0.20% |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 7.88% |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 26.09% |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -50.93% |
| 10 | Achieve Life Sciences | 330.88 Mn | 330.88 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2018 | 260.67% |
| Sep 30, 2018 | -54.47% |
| Jun 30, 2018 | -128.41% |
| Mar 31, 2018 | -189.91% |
| Dec 31, 2017 | 362.54% |
| Sep 30, 2017 | 319.88% |
| Jun 30, 2017 | 304.92% |
| Mar 31, 2017 | 490.96% |
| Dec 31, 2016 | 204.17% |
| Sep 30, 2016 | 150.72% |
| Dec 31, 2015 | 114.02% |
| Dec 31, 2012 | 56.70% |
| Sep 30, 2012 | -96.32% |
| Jun 30, 2012 | -97.49% |
| Mar 31, 2012 | -136.96% |
| Dec 31, 2011 | -204.16% |
| Sep 30, 2011 | 1.84% |